Bedrijfsoverzicht
ZeroStack Corp., ticker symbol FLGC, operates as an AI-powered asset management entity within the financial services sector, specifically focusing on the asset management industry. The company's business model involves providing decentralized AI solutions while simultaneously engaging in the distribution of pharmaceutical goods and medical cannabis products designed to treat various health indications, including cancer therapies. As of the latest available data, the company maintains a market capitalization of $21.59M and employs a workforce of 64 individuals to support its operations. With annual revenue reaching $57.61M, the valuation metrics suggest that the market values the company at a discount relative to its sales figures, indicating a small-cap position that relies heavily on operational expansion rather than established profitability. The combination of high-growth technology initiatives and regulated healthcare distribution creates a unique operational profile, yet the modest employee count relative to the revenue base highlights an aggressive scaling strategy typical of early-stage growth companies in the asset management and biotech-adjacent sectors.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $57.61M, yet generated a net income of -$15,921,000 and an EBITDA of -$13,713,000. The significant gap between total revenue and net income reveals a cost structure characterized by substantial operating expenses that consume more than half of the generated income, resulting in a profit margin of -27.7%. This negative profitability is further underscored by an operating margin of -33.5% and a gross margin of 21.0%, indicating that while the core business generates a positive spread on sales, overhead costs related to AI development and distribution logistics are eroding overall earnings. Regarding liquidity, the company holds $13.10M in cash against $3.25M in debt, resulting in a debt-to-equity ratio of 5.00, which suggests a highly leveraged balance sheet where equity capital is minimal compared to obligations. Despite the leverage, the current ratio stands at 2.08, indicating that the company possesses sufficient short-term liquid assets to cover its current liabilities more than twice over. Free cash flow for the period was -$4,575,625, which limits financial flexibility by necessitating ongoing reliance on external capital or existing cash reserves to fund operations and prevent liquidity crises. Return on Equity stands at -45.3% and Return on Assets at -17.5%, metrics that reveal that management is currently unable to generate returns on the capital invested in the business, a common characteristic for high-burn growth firms but one that signals a lack of immediate value creation.
Waarderingsbeoordeling
The valuation metrics present a complex picture, with a forward P/E of -8.52 while the trailing P/E is listed as N/A due to the company's consistent losses over the trailing twelve months. The absence of a positive trailing P/E implies that earnings are currently negative, rendering traditional price-to-earnings comparisons invalid and shifting focus to alternative valuation methods. The price-to-book ratio is 0.10, indicating that the market values the company at a fraction of its net asset value, suggesting a deep discount relative to the book value of its assets. Additionally, the price-to-sales ratio of 0.37 and an EV/EBITDA of 0.08 suggest that the stock is priced extremely low relative to its revenue generation and enterprise value, often seen in distressed or highly speculative growth plays. The stock has traded between a 52-week low of $5.86 and a 52-week high of $47.00, meaning the current market price sits significantly below the recent peak, reflecting investor caution regarding the negative earnings trajectory. With a beta of 1.90, the stock exhibits high price volatility, moving nearly twice as much as the broader market in response to changes in investor sentiment or sector-specific news.
Growth & Income
Revenue growth year-over-year stands at 34.7%, demonstrating a rapid expansion in top-line sales, whereas earnings growth is listed as N/A due to the persistent net losses. The divergence between strong revenue growth and negative earnings indicates that the company is prioritizing market share acquisition and product rollout over immediate profitability, a strategy that requires sustained capital injection to eventually turn earnings positive. As the company does not pay a dividend, with a dividend yield of N/A and a payout ratio of 0.0%, all available earnings are technically retained, though these earnings remain negative. Consequently, the company reinvests its operational resources and cash reserves into growth initiatives rather than returning capital to shareholders, which is typical for firms in the early stages of their lifecycle. The overall growth and income profile is defined by aggressive top-line expansion coupled with significant cash burn and no current income distribution to investors.